

Resource Summary Report

Generated by PRECISE-TBI on Sep 5, 2026

Akt (pan) (40D4) Mouse mAb

RRID:AB_1147620

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2920, RRID:AB_1147620

Antibody Information

URL: http://antibodyregistry.org/AB_1147620

Proper Citation: Cell Signaling Technology Cat# 2920, RRID:AB_1147620

Target Antigen: Akt (pan) (40D4) Mouse mAb

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F

Antibody Name: Akt (pan) (40D4) Mouse mAb

Description: This monoclonal targets Akt (pan) (40D4) Mouse mAb

Target Organism: rat, h, m, mouse, r, non-human primate, human, mk

Antibody ID: AB_1147620

Vendor: Cell Signaling Technology

Catalog Number: 2920

Alternative Catalog Numbers: 2920S

Record Creation Time: 20231110T074338+0000

Record Last Update: 20260829T043832+0000

Ratings and Alerts

No rating or validation information has been found for Akt (pan) (40D4) Mouse mAb.

No alerts have been found for Akt (pan) (40D4) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 191 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Radke K, et al. (2026) Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma. *EMBO molecular medicine*, 18(2), 433.

Pendyala S, et al. (2026) Image-based, pooled phenotyping reveals multidimensional, disease-specific variant effects. *Cell*, 189(13), 4040.

Chien JY, et al. (2026) Nostoc commune Extract Attenuates Oxidative Stress and Neuroinflammation in Ischemic Optic Neuropathy Through PI3K/AKT/mTOR Signaling. *Antioxidants (Basel, Switzerland)*, 15(5).

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Park C, et al. (2026) A Rasa3-G β i signaling axis orchestrates B lymphocyte trafficking into and through lymphoid organs. *Cell reports*, 45(4), 117243.

Wang Z, et al. (2026) Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e15158.

Zorn A, et al. (2026) The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells. *British journal of pharmacology*.

Norambuena-Soto I, et al. (2026) Angiotensin-(1-9) attenuates diabetic cardiomyopathy by improving insulin resistance. *British journal of pharmacology*, 183(11), 3032.

Ma K, et al. (2026) ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. *Cell*, 189(11), 3413.

Garczyk M, et al. (2026) Targeting PI3K γ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. *Cell reports*, 45(4), 117188.

Gilbert AE, et al. (2026) Mtg16/Eto2 tumor suppressor maintains and establishes repression by distinct mechanisms. *Molecular cell*, 86(13), 2492.

Billmann M, et al. (2026) Global genetic interaction network of a human cell maps conserved principles and informs functional interpretation of gene co-essentiality profiles. *Cell*, 189(12), 3736.

Torosyan H, et al. (2026) Structures of the PI3K β /KRas complex on lipid bilayers reveal molecular mechanisms of PI3K β activation. *Molecular cell*, 86(14), 2858.

Fan J, et al. (2026) PDX1 phosphorylation at S61 by mTORC1 links nutrient signaling to β cell function and metabolic disease. *Cell reports*, 45(1), 116811.

Kral AJ, et al. (2026) Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. *Molecular cell*, 86(1), 60.

Cho H, et al. (2026) miR-181a post-transcriptionally targets GRK2 to limit maladaptive signaling in cardiomyocytes. *Frontiers in cardiovascular medicine*, 13, 1821660.

Luo YE, et al. (2026) Resident mesenchymal progenitor cells require autocrine IGF-I in homeostatic and regenerating skeletal muscle. *Stem cell reports*, 21(7), 102973.

Sunami T, et al. (2026) IGF2BP3 is essential for the growth heterogeneity of colorectal adenoma cells by regulating MYC. *iScience*, 29(7), 116535.

Decker M, et al. (2025) In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer. *bioRxiv : the preprint server for biology*.

Müller-Schiffmann A, et al. (2025) Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology. *Cell reports. Medicine*, 102520.